Insight Molecular Diagnostics Inc Dossier - Source-backed chat

Insight Molecular Diagnostics Inc

IMDXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.54

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.47Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $113.6M

Enterprise Value $98.9M

Shares Outstanding 37.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Insight Molecular Diagnostics Inc. (iMDx) is transitioning from a product development-stage company to a commercial-stage precision diagnostics player. Its flagship GraftAssure platform targets a $2 billion addressable market for kidney transplant rejection testing by offering a decentralized, kitted digital-PCR assay that allows transplant centers to perform testing in-house. While recent clinical data published in Clinical Chemistry and the American Journal of Transplantation demonstrate excellent concordance and statistical superiority of its CM-Score over single-metric dd-cfDNA tests, the company remains in an early commercial phase with minimal near-term revenue ($32k in Q1 2026) and a high cash burn rate ($9M projected for Q2 2026). A 'Hold' rating is warranted until FDA De Novo clearance for GraftAssureDx is secured and initial commercial traction is established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$8.33

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0015%

The FDA issues major deficiency letters or requests additional clinical validation studies for GraftAssureDx, stopping the review clock and delaying approval well into 2027. Delayed commercialization prevents the company from mitigating its cash burn, exhausting its cash reserves ($28.2M as of Q1 2026) and forcing highly dilutive equity raises or expensive debt financing.

Base CaseCentral scenario

$8.3360%

Matches the consensus mean

The FDA reviews the GraftAssureDx submission within standard timelines, leading to clearance in late 2026 or early 2027. The company successfully transitions registry sites to commercial accounts, generating modest initial kitted sales. Cash burn peaks in Q2 2026 at over $9M and declines to approximately $6M per quarter in H2 2026, supported by the $26M capital raise completed in February 2026. Revenue scales gradually in line with a measured commercial rollout.

Bull CaseUpside scenario

$12.0025%

The FDA grants De Novo marketing authorization for GraftAssureDx in late 2026, triggering rapid adoption across the 37 engaged U.S. transplant centers (representing >25% of annual U.S. transplants). Decentralized in-house testing displaces centralized send-out models due to faster turnaround times and lower costs. Commercial launch drives exponential revenue growth toward the consensus 2027 forecast of $254M, and cash burn declines rapidly as high-margin kit sales scale.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-ever kitted dd-cfDNA assay submitted for FDA De Novo review, offering a unique decentralized testing model for transplant centers.
Strong clinical validation with peer-reviewed data in Clinical Chemistry showing 99.2% concordance with leading NGS assays, and AJT data showing superior diagnostic performance of the GraftAssure CM-Score.
Established footprint with 37 U.S. transplant centers representing over 25% of annual U.S. transplant volume.
Strategic collaboration with Bio-Rad Laboratories leveraging established ddPCR instruments and reagents.

Key Investment Risks

High near-term cash burn ($9M+ in Q2 2026) relative to cash balance ($28.2M as of Q1 2026), presenting ongoing dilution risk.
Regulatory risk associated with the FDA De Novo review process, where questions can stop the 150-day review clock.
Commercial execution risk in transitioning transplant centers from established centralized send-out models (e.g., CareDx, Natera) to in-house kitted testing.

Thesis Invalidation Triggers

FDA rejection or a major delay (exceeding 6 months) in the regulatory review of GraftAssureDx.
Quarterly cash burn failing to decline below $8 million in H2 2026, indicating poor cost control.
A significant drop in transplant center engagement or registry participation.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.